NBIX vs REGN: How Neurocrine Biosciences and Regeneron Pharmaceuticals Compare (2026)
Short answer
NBIX (Neurocrine Biosciences) and REGN (Regeneron Pharmaceuticals) are often compared because they share investment themes, but they are different businesses. Neurocrine Biosciences makes money primarily from Ingrezza (valbenazine), an oral VMAT2 inhibitor for tardive dyskinesia and chorea associated with Huntington's disease, which generated about $657 million in net product sales in Q1 2026, up roughly 20 percent year over year, with full-year 2026 guidance of about $2.7 to $2.8 billion. Regeneron makes money primarily through two large franchises. Neither is universally better: pick by which thesis you are expressing and what you already own. This is descriptive, not a recommendation.
What does Neurocrine Biosciences (NBIX) do?
Neurocrine Biosciences makes money primarily from Ingrezza (valbenazine), an oral VMAT2 inhibitor for tardive dyskinesia and chorea associated with Huntington's disease, which generated about $657 million in net product sales in Q1 2026, up roughly 20 percent year over year, with full-year 2026 guidance of about $2.7 to $2.8 billion. A second product, Crenessity (crinecerfont), launched for classic congenital adrenal hyperplasia and contributed about $153 million in Q1 2026, helping total quarterly revenue grow roughly 44 percent to about $815 million. The company is solidly profitable, reporting Q1 2026 net income near $198 million.
What does Regeneron Pharmaceuticals (REGN) do?
Regeneron makes money primarily through two large franchises. Dupixent, an anti-inflammatory antibody used for eczema, asthma, COPD, and other conditions, is developed and commercialized in collaboration with Sanofi, and Regeneron records its share through Sanofi collaboration revenue (about $1.6 billion in Q1 2026, up roughly 36%). Eylea and the higher-dose Eylea HD treat retinal diseases such as wet age-related macular degeneration and diabetic eye disease, generating combined U.S. net product sales of about $941 million in Q1 2026, with Eylea HD now roughly half of that mix. Libtayo in oncology and a pipeline of nearly 50 clinical candidates round out the revenue base.
NBIX vs REGN: how do they differ?
Both fit overlapping themes, but they are not interchangeable. Neurocrine Biosciences is best understood through its own drivers, and Regeneron Pharmaceuticals through its. The useful comparison is which set of drivers and risks you want exposure to.
- NBIX drivers: Ingrezza is a durable, growing cash engine; Crenessity adds a real second product.
- REGN drivers: Dupixent keeps compounding; A deep, diversified pipeline.
NBIX vs REGN: how they make money and what they cost
NBIX. Figures are approximate and tied to the asOf date, drawn from Q1 2026 results and mid-2026 market data. Neurocrine trades at a trailing P/E near 25x, a premium to the broader biotech group that reflects its profitability and pipeline optionality. Total Q1 2026 revenue grew about 44 percent year over year to roughly $815 million as Crenessity scaled alongside Ingrezza.
REGN. Figures are approximate and tied to the asOf date; verify current numbers with a live quote before acting. Regeneron reported about 19% revenue growth and adjusted EPS of roughly $9.47 in Q1 2026, beating estimates, and authorized an additional $3 billion buyback. The mid-teens P/E reflects the market weighing strong Dupixent growth against expected Eylea biosimilar erosion.
Headline figures (approximate, 2026-06-27): NBIX shows revenue (ttm) ~$2.9 billion, ingrezza net sales (q1 2026) ~$657 million, crenessity net sales (q1 2026) ~$153 million; REGN shows total revenue (ttm, approx) ~$14 billion, q1 2026 total revenue ~$3.6 billion (up ~19% YoY), dupixent global net sales (q1 2026) ~$4.9 billion (up ~31%). A cheaper-looking multiple is not automatically the better buy: a richer valuation can be justified by faster growth, and a lower one can reflect real risk. Weigh the multiple against how fast each business is actually compounding.
Which fits which kind of investor
Both share a theme, but they suit different temperaments. Neurocrine Biosciences's case leans on ingrezza is a durable, growing cash engine, and Regeneron Pharmaceuticals's on dupixent keeps compounding. A faster-growing, richer-valued name usually swings harder, so it suits a longer horizon and a higher tolerance for volatility; a steadier, more cash-generative business suits a more conservative or income-minded investor. The honest test is which set of risks you could hold through a drawdown: The dominant risk is concentration: Ingrezza still drives the majority of revenue, so any erosion from new VMAT2 competition, formulary or payer pressure, or pricing reform would hit results disproportionately. For REGN, the clearest risk is Eylea biosimilar erosion.
NBIX or REGN: which should you pick?
The bottom line: NBIX vs REGN
NBIX and REGN are related but distinct: same themes, different businesses and risks. Neither wins in the abstract; the right pick is whichever thesis you actually believe, sized so you are not over-concentrated in one theme. Walnut can show your combined NBIX and REGN exposure against your real portfolio. It is not an investment adviser.
Build a basket around NBIX with Walnut
Use Neurocrine Biosciences as one constituent in a thematic basket Walnut's AI helps you assemble. Describe a thesis you believe in, the AI proposes the holdings and weights, and you approve before any broker order.
FAQ
What is the difference between NBIX and REGN?
+
Neurocrine Biosciences makes money primarily from Ingrezza (valbenazine), an oral VMAT2 inhibitor for tardive dyskinesia and chorea associated with Huntington's disease, which generated about $657 million in net product sales in Q1 2026, up roughly 20 percent year over year, with full-year 2026 guidance of about $2.7 to $2.8 billion. Regeneron makes money primarily through two large franchises. They show up together because they share investment themes, but they are different businesses, so the better fit depends on which thesis you are expressing.
Is NBIX or REGN the better stock?
+
Walnut is informational, not investment advice. Neither is universally better; NBIX and REGN suit different views and risk levels. Compare what each does, how they make money, and the risks, then decide which fits your thesis and what you already own.
Should you own both NBIX and REGN?
+
Because they share themes, owning both concentrates you in that theme. That can be intentional (a focused bet) or accidental (less diversification than it looks). Walnut can show your combined exposure across both before you add the second.
What are the risks of NBIX vs REGN?
+
NBIX: The dominant risk is concentration: Ingrezza still drives the majority of revenue, so any erosion from new VMAT2 competition, formulary or payer pressure, or pricing reform would hit results disproportionately. CNS drug development is also high-risk, and a single Phase 3 miss for the muscarinic program or other pipeline candidates could sharply reset expectations. Large acquisitions like Soleno add integration and execution risk, and the stock can be volatile around trial readouts, label decisions, and guidance updates. REGN: The clearest risk is Eylea biosimilar erosion. Amgen's Pavblu launched in late 2024 and pressured sales, and settlements clear paths for Sandoz, and Alvotech and Teva, to launch competing copies in the U.S. around the fourth quarter of 2026, with erosion expected to accelerate. Eylea HD and Dupixent growth are the offsets, but the timing gap matters. The business is also concentrated in a few franchises, so a single setback in Dupixent or a major pipeline failure would weigh heavily, and the collaboration structure with Sanofi means Regeneron does not control all of its largest product's economics.
Walnut is informational, not investment advice. This page is descriptive and not a recommendation to buy or sell NBIX or REGN; figures are approximate and dated. Verify current data before investing.